Menarini Diagnostics and Nucleix Partner for Bladder EpiCheck test

Menarini Diagnostics and Nucleix have agreed to exclusively distribute the Bladder EpiCheck test in Europe, announced at the 36th European Congress of Pathology in Florence. Menarini Diagnostics brings advanced solutions to the in vitro diagnostic market while Nucleix is revolutionizing cancer treatment by detecting the disease earlier.

This CE-marked test is non-invasive and can identify primary or recurrent bladder cancer as well as upper tract urinary cancer. Bladder EpiCheck is recommended in the European Association of Urology (EAU) Clinical Guidelines as a urine test that can be utilized in the initial diagnosis of bladder cancer to potentially eliminate the need for cystoscopy, and in follow-up to detect recurrence of non-muscle invasive bladder cancer (NMIBC) tumors as an alternative to delaying or avoiding cystoscopy. The exam is also part of the EAU Clinical Guidelines as a supplementary tool in the detection and tracking of UTUC.

Bladder cancer ranks as the sixth most prevalent cancer, with around 760,000 individuals in Europe affected by the illness. Monitoring is crucial for NMIBC patients because of the elevated rates of recurrence and potential advancement to life-threatening illness. High-risk NMIBC patients may need to have invasive cystoscopies every three months during their follow-up appointments. Bladder EpiCheck offers a non-invasive monitoring test that can identify high-grade disease early, potentially reducing the need for cystoscopies and easing the burden of bladder cancer surveillance for both patients and health systems. This improves patient outcomes by targeting intervention to those who will benefit most.